Tirzepatide has become one of the most effective medications available for weight management, and one of the most confusing to shop for. Prices vary wildly, the rules around compounded versions changed completely in the last eighteen months, and a great deal of what you’ll read online is written by people selling something.
This page is our attempt at a straight answer. I’m a practicing physician, and what follows is what I’d tell a patient sitting across from me.
— Dr. Rick Spurlock, PhySlim
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide acts on one receptor pathway; tirzepatide acts on two. In practice that dual action tends to produce greater appetite suppression and, in head-to-head trial data, greater average weight reduction.
It’s sold under two brand names:
Same molecule, different approved indication and different packaging.
Yes. It’s a synthetic peptide — a chain of amino acids engineered to bind both receptors. That’s worth knowing because “peptide” has become a marketing word attached to a lot of unregulated products. Tirzepatide in its FDA-approved form is a prescription drug manufactured to pharmaceutical standards. That is not the same category as peptides sold online.
On average, trial data favors tirzepatide for total weight reduction. But “on average” does a lot of work in that sentence. Tolerability differs between individuals, insurance coverage differs, and the best drug is the one a particular patient can actually take consistently and afford. We’ve had patients do better on semaglutide after struggling with tirzepatide, and the reverse. That’s a conversation, not a spreadsheet.
This is where most of the confusion sits, so it’s worth being precise — including about what we offer and why.
When tirzepatide was in official shortage, compounding pharmacies could produce copies of it, and a large market grew up around cheap compounded vials sold largely online. That shortage was declared resolved in December 2024. FDA has since moved to exclude tirzepatide permanently from the 503B bulk drug substances list. Compounding that simply replicates the FDA-approved product is no longer a legitimate pathway.
If someone is still selling you a cheap copy of Zepbound in a vial, that is the market that closed. Ask hard questions.
We prescribe a combination formulation — tirzepatide with L-carnitine — compounded patient-specifically by a 503A pharmacy. That is not a copy of the approved drug. It is a distinct formulation, prescribed when there is a documented clinical reason the approved product doesn’t address a particular patient’s situation.
The distinction matters legally and clinically, and we don’t blur it.
This is a clinical determination made at a visit, not a menu option. The situations where we’ve found the combination worth considering:
Tirzepatide acts on appetite regulation and glucose handling through dual incretin action. That part is well established and carries the bulk of the effect.
L-carnitine’s role is in fatty acid transport into the mitochondria, the step that makes stored fat available to be burned as fuel. I want to be straight with you about the strength of that evidence: randomized trial data on oral L-carnitine supplementation shows a modest effect on body weight in adults with overweight and obesity, on the order of about a kilogram across 37 trials. Effects on waist circumference and body fat percentage were not statistically significant.
We use the injectable form, where absorption isn’t limited the way it is with oral dosing. But I’d rather you understood it as one component of a combination approach aimed at the metabolic picture, not as a weight-loss agent in its own right. The tirzepatide is doing the heavy lifting.
If a clinic tells you the carnitine is what makes their formula special, be skeptical.
For our formulation, your starting dose is determined at your visit and written on your prescription. It depends on the concentration we’ve specified and your individual titration plan.
For a vial from anywhere else: we can’t tell you, and neither can anyone else safely. Concentrations differ between pharmacies, and a dose that’s correct at one concentration is a serious overdose at another. See below.
For many patients, FDA-approved tirzepatide is the right choice, and manufacturer direct-pay programs have narrowed the price gap considerably. Lilly sells Zepbound directly to patients through LillyDirect, and Novo Nordisk does the same for Wegovy through NovoCare Pharmacy. Both are substantially below the old list prices, and most people have never heard of either. If you are on Medicare Part D, there is a separate route again — the Medicare GLP-1 Bridge — which matters because the manufacturers’ savings cards specifically exclude anyone on Medicare, Medicaid or TRICARE. That exclusion catches a lot of people out.
What we do is work out which of those you actually qualify for, and then handle the part that stops most people: checking your plan’s formulary, confirming whether weight management is covered at all, and writing and submitting the prior authorization with the clinical documentation it needs. We prescribe the approved product where that is the right answer. We’ll tell you which route we think fits you, including when that’s the approved product rather than ours.
We’re answering this because people search for it constantly, and the answer they usually find is wrong in a way that can hurt them.
FDA-approved tirzepatide is dosed in milligrams, delivered by a pre-filled pen that administers a fixed dose. There are no units to convert. The question only arises with compounded vials drawn up using insulin syringes, which are marked in units.
The conversion depends entirely on the concentration of that particular vial. A vial at one concentration and a vial at another require completely different volumes for the same milligram dose. There is no universal conversion, and using a number you found online against a vial from a different pharmacy is how people end up in the emergency department.
If you are holding a compounded vial and you are not certain of its concentration and your prescribed dose in units, stop and call the prescriber who wrote it. Do not calculate it yourself from a website. That includes this one.
At your first visit we take a full history, review your medications, and order baseline labs: a complete blood count (CBC), a comprehensive metabolic panel (CMP), and a thyroid-stimulating hormone (TSH) level. Those cover your blood counts, kidney and liver function, electrolytes, blood sugar and thyroid status — the things that either change what we prescribe or need watching once you are on it. We’re looking at thyroid history, pancreatitis history, gallbladder disease, kidney function, and whether there’s a personal or family history of medullary thyroid carcinoma or MEN2 — which are contraindications, not cautions.
Treatment starts low and increases gradually. The standard schedule begins at 2.5 mg weekly for four weeks before any increase. Going up faster does not speed up results; it produces nausea and people quit.
Monthly at first. While the dose is still moving is exactly when tolerance, side effects and titration decisions need an actual conversation, so we want eyes on you during that stretch.
Once you are on a stable dose and tolerating it well, visits spread out. Settled patients can go several months between appointments. There is no value in bringing you in to tell you nothing has changed, and we do not pretend otherwise.
Tirzepatide reduces appetite. It does not build the habits that keep weight off afterward, and it does not protect the muscle you lose when weight comes off quickly. So the medication is one part of what we do, not the whole of it.
We measure your resting metabolic rate — what your body actually burns at rest, which is not what an online calculator estimates — and build a nutrition plan around that number, weighted toward protein so you hold onto muscle while the fat comes off.
Every follow-up visit includes body composition analysis. Not weight. Not BMI. Muscle mass, fat mass and water, measured and tracked across your whole course of treatment.
If you do not know where you are, it is hard to see where you are going.
Two things make up your cost: the visit, and the medication.
Visits are a flat fee. Your first appointment is a full in-person evaluation with a medical provider, including history, medication review and the baseline labs we order. Follow-up visits are shorter, cost less, and include body composition analysis.
Medication is priced by your weekly dose and dispensed monthly. Lower starting doses cost less than higher maintenance doses, so what you pay in month one is not what you pay at a full dose.
What we charge for our compounded formulation is not the price of Zepbound. They are different products on different pricing. If the FDA-approved product is the better route for you — and for some patients it is — we will say so, and manufacturer self-pay pricing is published on Lilly’s own site.
Call us or ask at your visit and we will give you the exact figure for your dose. No quote-on-request games; we just have not put the table on this page yet.
The common ones are gastrointestinal: nausea, vomiting, diarrhea, constipation. They’re most pronounced after a dose increase and usually settle. Eating smaller portions, slowing down, and avoiding high-fat meals helps more than most people expect.
Fatigue is reported, particularly early on. Much of it is likely secondary to eating substantially less rather than a direct drug effect. If you cut your intake sharply, you will feel it. Worth reviewing with us rather than pushing through, because it can also signal inadequate protein intake or dehydration.
Hair shedding is reported by some patients. The current understanding is that this reflects telogen effluvium — the shedding that follows any rapid weight loss or physiological stress — rather than a direct effect of the drug on hair follicles. It’s typically temporary. Adequate protein intake and a slower rate of loss both help.
If shedding persists once your weight has stabilized, or if there is underlying pattern hair loss the weight change has simply unmasked, that is a different problem and it is worth evaluating separately. We do prescribe compounded topical hair-growth formulations, including:
Which one, if any, depends on the pattern of loss and your own history. Several of these contain finasteride or dutasteride, which can cause birth defects and must not be used or handled by anyone who is pregnant or may become pregnant. That is a conversation to have at a visit, not a product to pick off a list.
Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Pancreatitis, gallbladder disease and severe gastrointestinal reactions have been reported. This is a real medication with real risks, which is the argument for physician supervision rather than a website that mails you a vial.
Appetite suppression is often noticeable within the first week or two. Meaningful weight change takes longer. Most patients see steady reduction over the first three months, with results continuing to build as the dose is titrated up.
If nothing has changed after two months, that is a reason to reassess rather than wait it out.
Subcutaneous injection into the abdomen (avoiding the area immediately around the navel), the front of the thigh, or the back of the upper arm. Rotate the site each week rather than using the same spot repeatedly.
We walk every patient through their first injection in person.
And if you would rather not inject yourself at all, you do not have to. We can keep your vial here, labeled and stored for you, and you come in to have it given. Which days and hours that is available differs by location, so ask us what works at the site you use.
Your first visit is in person and takes about 45 minutes. We go through your full history, review everything you are currently taking, and order baseline labs.
Depending on what that history shows, treatment may start the same day or we may wait for lab results first. That is a clinical judgment rather than a fixed rule, and we will tell you which one applies to you and why. The labs matter either way — they shape how we manage you from there.
You do not need a referral. Bring a list of your current medications and supplements, and your insurance card if you have coverage — even if you expect it not to cover weight management, it is worth checking rather than assuming.
We will also go through the four ways people actually pay for this: insurance, the manufacturers’ self-pay programs, the Medicare route, and our own compounded formulation. Which one fits you depends on your plan, your dose and your diagnosis, and it is a five-minute conversation rather than a guess.
Most of our new patients can be seen within the week. Book now, or call or text with questions.
Yes. Tirzepatide is a synthetic peptide — a chain of amino acids engineered to bind both the GIP and GLP-1 receptors. In its FDA-approved form it is a prescription drug manufactured to pharmaceutical standards, which is a different category from peptides sold online.
On average, trial data favors tirzepatide for total weight reduction. But tolerability, cost and coverage differ between individuals. The better drug is the one you can take consistently and afford, which is a decision made at a visit rather than from a chart.
Not as a cheap copy of the approved drug — that pathway closed when the shortage resolved in December 2024. We prescribe a tirzepatide with L-carnitine combination formulation, compounded patient-specifically where there is a documented clinical reason the approved product doesn’t fit.
There is no universal conversion. FDA-approved tirzepatide is dosed in milligrams via a fixed-dose pen. The units question only applies to compounded vials, and the answer depends on that specific vial’s concentration. Call your prescriber rather than using a number from the internet.
Appetite suppression is often noticeable within one to two weeks. Meaningful weight change builds over the first three months and continues as the dose is titrated upward.
Some patients experience shedding. This is generally telogen effluvium — the shedding that follows rapid weight loss or physiological stress — rather than a direct effect on hair follicles. It is usually temporary, and adequate protein intake helps.
Fatigue is commonly reported early in treatment. Much of it likely reflects eating substantially less rather than a direct drug effect. It can also signal inadequate protein or dehydration, so it is worth raising with us rather than tolerating.
Subcutaneously into the abdomen (avoiding the area right around the navel), the front of the thigh, or the back of the upper arm. Rotate the injection site each week.
We take a full history, review your medications and order baseline labs at your first visit, screening for contraindications including personal or family history of medullary thyroid carcinoma and MEN2. Whether treatment starts that same day or waits for those results is a clinical judgment we make case by case, and we tell you which applies to you and why.
Medically reviewed by Richard G. Spurlock, MD
Board-certified in emergency medicine by the American Board of Emergency Medicine. Undergraduate at the University of Florida, medical degree from the University of Miami Miller School of Medicine, and emergency medicine residency at Emory University. Practicing emergency medicine since 2007. He founded PhySlim in 2013 and still works clinical shifts alongside running it.
Last reviewed: August 16, 2026
More about Dr. Spurlock
